Using neutralizing β1 integrin mAb in vivo (39), we demonstrated that β1 integrin is required for early mTOR activation and leukocyte recruitment in mitral valve disease as well as the later development of ECM changes characteristic of mitral valve degeneration. This evidence concerns the gene MTOR and mitral valve disorder.